Efficacy Of Tezepelumab In Patients With Severe, Uncontrolled Asthma By Specific Perennial Allergen Immunoglobulin E Thresholds

Abstract

Allergic asthma is the most common type of asthma. The presence of allergen-specific IgE is synonymous with sensitization to that allergen, and often correlates with perennial allergy. A threshold of ≥0.35 kUA/L is generally used to define a positive result, but higher concentrations may indicate a greater degree of sensitivity. Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. This post hoc analysis evaluated the efficacy of tezepelumab, using pooled data from phase 2b PATHWAY (NCT02054130) and phase 3 NAVIGATOR (NCT03347279) studies, in patients with perennial allergy grouped by different thresholds of serum specific IgE.